Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Review
.2013 May;110(5):690-701.
doi: 10.1093/bja/aet068.

Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions

Affiliations
Review

Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions

J P Cata et al. Br J Anaesth.2013 May.

Abstract

Debate on appropriate triggers for transfusion of allogeneic blood products and their effects on short- and long-term survival in surgical and critically ill patients continue with no definitive evidence or decisive resolution. Although transfusion-related immune modulation (TRIM) is well established, its influence on immune competence in the recipient and its effects on cancer recurrence after a curative resection remains controversial. An association between perioperative transfusion of allogeneic blood products and risk for recurrence has been shown in colorectal cancer in randomized trials; whether the same is true for other types of cancer remains to be determined. This article focuses on the laboratory, animal, and clinical evidence to date on the mechanistic understanding of inflammatory and immune-modulatory effects of blood products and their significance for recurrence in the cancer surgical patient.

PubMed Disclaimer

Figures

Fig 1
Fig 1
The figure illustrates the interaction between cellular and humoral responses against cancer cells. The cellular immune response is composed of Th1 and Tc1 (anti-tumour) and Th2 and Tc2 (pro-tumoral) lymphocytes. Similarly, the cytokine immune response is accomplished by Th1 (IL-2, IL-12, IFN-γ, and TNF-γ) predominantly antitumour cytokines; in contrast, the Th2 cytokines (IL-4, IL-5, IL-6, and IL-10) have mainly pro-tumour actions.
See this image and copyright information in PMC

Comment in

References

    1. Asahara T, Katayama K, Itamoto T, et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg. 1999;23:676–80. - PubMed
    1. Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 2009;13:1636–42. - PubMed
    1. Tomimaru Y, Wada H, Marubashi S, et al. Fresh frozen plasma transfusion does not affect outcomes following hepatic resection for hepatocellular carcinoma. World J Gastroenterol. 2010;16:5603–10. - PMC - PubMed
    1. Sugita S, Sasaki A, Iwaki K, et al. Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol. 2008;34:339–45. - PubMed
    1. de Boer MT, Molenaar IQ, Porte RJ. Impact of blood loss on outcome after liver resection. Dig Surg. 2007;24:259–64. - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp